HK Stock Market Move | TYK MEDICINES-B(02410) rose nearly 5% in the afternoon. Axitinib tablets have been included in the list of priority review varieties.

TYK Medicines-B (02410) rose nearly 5% in the afternoon, rising 3.65% as of the press release to 13.06 Hong Kong dollars with a trading volume of 28.9062 million Hong Kong dollars. In terms of news, Tongyuan Kang Medicine previously announced that the company's investigational new drug AdoTrini hydrochloride tablets (TY-9591 tablets) have been included in the priority review list by the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE). It is reported that the drug is intended for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) adult patients with exon 19 deletion or exon 21 substitution mutations in the epidermal growth factor receptor (EGFR) and central nervous system metastases. Being included in priority review marks that the review process of AdoTrini hydrochloride tablets will be accelerated comprehensively, and it is expected to be marketed earlier, providing new treatment options for Chinese patients.